when were glp 1 drugs approved Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Figure 2, Health Canada Approval
Description
These biomarkers could possibly be used to monitor and document disease progression

When you lose weight, you run the risk of bone loss, said Apovian, who was not involved in the study

Even my sisters askin what Im doin different

Exposure to glucagon-like peptide 1 receptor agonists does not increase the risk of AKI associated with anticancer therapy: FR-OR80

Weight loss is beneficial for PsO and HS outcomes, through a reduction in the inflammatory component of CVR

The drugs also seem to reduce inflammation, which may help to reduce risk of cancer
